Increased plasma pancreatic polypeptide (PP) in diabetic ketoacidosis; normalization following treatment.
As both hypoglycaemia and hyperglycaemia may modify plasma levels pancreatic polypeptide (PP), we measured plasma PP by a homologous radioimmunoassay in seven diabetics who were admitted to the hospital in overt diabetic ketoacidosis (initial blood glucose 27.1-55.0 mmol/l). None had circulating PP-antibodies. All were treated with continuous infusion of insulin and fluids. Before starting treatment, plasma PP ranged from 2585-136 mmol/l (mean 629 pmol/l). Following treatment plasma PP decreased gradually in all patients. The following morning mean plasma PP was 242 pmol/l, 67 pmol/l when one ureamic patient was excluded. The normal value is less than 100 pmol/l. This study shows that plasma PP is clearly elevated in diabetic ketoacidosis and decreases following treatment.
D000328:Adult; D000368:Aged; D016883:Diabetic Ketoacidosis / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010191:Pancreatic Polypeptide / Q000097:blood*
D007328:Insulin; D010191:Pancreatic Polypeptide